The $40 Million Bet

RICHMOND, VIRGINIA — On January 21, 2026, AnswersNow announced that it had raised $40 million in Series B funding led by HealthQuest Capital, with participation from existing investors Left Lane Capital and Owl Ventures. The round brings AnswersNow’s total funding to $66 million—an investment of institutional-scale capital into a company that delivers ABA therapy entirely through a virtual platform, without a single physical clinic.

HealthQuest Capital, a private asset firm with approximately $2 billion in capital under management, focuses on transformative healthcare companies across medical technologies, diagnostics, digital health, and innovative services. Left Lane Capital, a New York and London–based venture capital firm investing in high-growth consumer technology businesses, participated as a returning investor. Owl Ventures, an education-focused venture fund, also joined the round.

The investment thesis is direct. Sam Brasch, a partner at HealthQuest Capital, stated that the autism support system in America is broken, leaving families to wait months or longer for services at untenable costs for insurers. Henry Toole, a partner at Left Lane Capital, noted that autism is the fastest-growing developmental disability in America, with one in every 31 children being diagnosed, and that the widening gap in support services means most families are forced to wait months or longer for a first appointment. AnswersNow claims it can eliminate that waitlist by connecting families with BCBAs within five days.

AnswersNow claims 75 percent cost reduction for payers and clinically significant outcomes with one-sixth the therapy hours. If the data holds up, it is the most disruptive unit economics model in ABA—and the most significant PE bet against the brick-and-mortar thesis.

The Model: How AnswersNow Works

AnswersNow’s care model departs fundamentally from traditional ABA delivery. Traditional center-based ABA typically involves 25 to 40 hours per week of direct therapy, delivered primarily by Registered Behavior Technicians under BCBA supervision, in a clinic setting. The model is labor-intensive, facility-dependent, and expensive: annual treatment costs can exceed $200,000 without robust insurance coverage.

AnswersNow replaces this model with virtual one-on-one therapy sessions delivered exclusively by BCBAs—PhD- and Master’s-level clinicians—rather than by behavior technicians. The company’s AI-powered platform generates individualized learning modules that adapt to each child’s interests and engagement patterns. Therapy is delivered in approximately 4 to 5 hours per week, compared to the traditional 30-plus hours. The model is parent-mediated: BCBAs train caregivers to reinforce skills during everyday interactions, extending the therapeutic impact beyond scheduled sessions.

The clinical claims are striking. AnswersNow reports that within the first six months of care, 96 percent of families report meaningful improvements in behavior and communication, children demonstrate clinically significant gains on standardized assessments (specifically, Vineland Adaptive Behavior Scales improvements), and the company has maintained a Net Promoter Score of 83. The company facilitated nearly 100,000 hours of virtual ABA therapy and caregiver training in 2025, and it announced plans to publish first-of-its-kind research in early 2026 documenting its outcomes and efficiency at scale.

For payers, the economics are compelling. AnswersNow claims cost savings of up to 75 percent compared to traditional ABA delivery—achieved through the dramatic reduction in therapy hours and the elimination of facility costs. The company is available as in-network coverage through commercial insurers and Medicaid plans in multiple states, positioning it as a mainstream rather than out-of-network alternative.

Virtual-First vs. Brick-and-Mortar: The Defining PE Debate

The AnswersNow investment forces a direct comparison with the PE-backed brick-and-mortar platforms that have defined ABA M&A for the past decade. Companies like ACES (92 locations, General Atlantic), BlueSprig (100-plus locations, KKR), Behavioral Innovations (77 locations, Tenex Capital), and Proud Moments ABA (70-plus locations, Nautic Partners) have built their platforms through physical clinic expansion and acquisition. Their economics depend on facility utilization, geographic density, and the labor of RBTs delivering high-volume direct therapy hours.

AnswersNow’s model eliminates the facility, eliminates the RBT labor dependency, and compresses therapy hours by more than 80 percent. If the clinical outcomes are genuinely equivalent—a claim that the company plans to substantiate through published research—the virtual-first model has structural advantages in scalability, unit economics, and geographic reach. A BCBA delivering virtual therapy from Richmond, Virginia, can serve families in any state where AnswersNow holds licensure, without the constraints of clinic buildout, lease negotiation, or local labor market dynamics.

The skeptics’ argument is equally direct. ABA therapy works, in significant part, through the intensive, consistent, daily intervention that traditional models provide. Reducing therapy from 30 hours per week to 5 hours per week is not a minor adjustment—it is a 83 percent reduction in treatment intensity. The clinical literature on ABA dosage consistently shows that higher treatment intensity is associated with better outcomes, particularly for young children with more significant support needs. If AnswersNow’s outcomes are driven by selection effects—enrolling higher-functioning children who would have improved with less intervention regardless—rather than by the efficiency of the model itself, the comparison to traditional ABA is misleading.

The resolution of this debate will depend on the data. AnswersNow’s planned publication of outcomes research will be the most scrutinized clinical study in ABA in years. If the data shows genuinely equivalent or superior outcomes across the severity spectrum—including children with significant behavioral challenges and communication deficits—the virtual-first model will gain enormous credibility with payers, providers, and regulators. If the data shows favorable outcomes primarily for higher-functioning populations, the model’s applicability will be narrower—valuable but not paradigm-shifting.

CEO Jeff Beck stated that by exclusively using Master’s- and PhD-level BCBAs for targeted parent training, combined with AI-enabled focused therapy for children, AnswersNow can achieve equal or better outcomes at a fraction of the time and cost. The market is about to find out whether the data supports that claim. The $40 million bet from HealthQuest, Left Lane, and Owl Ventures says the smart money thinks it will.

AT A GLANCE

SOURCES & REFERENCES